An end to chasing structures that were never there
Advertisement
Research describes a rapid computational method for identifying incorrect molecular structures that have been mistakenly determined using misassigned NMR signals.
Ariel Sarotti, a scientist in Argentina, has developed a tool that combines calculated and experimental 13C NMR data to flag up incorrectly determined structures. NMR spectroscopy is a standard tool for elucidating the structure of organic molecules, but in the case of complex molecules, where many signals are present in a spectrum, structural determination becomes much more difficult and errors can result in the wrong structure being proposed.
Sarotti’s method uses trained artificial neuron networks to find patterns in both the calculated and experimental data to do the decision-making. A set of 200 molecules with known correct and incorrect NMR assignments was used to create and train the system. The subsequent testing phase correctly identified the incorrect structures of a set of 26 natural products.
Most read news
Original publication
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
D-Cycloserine Reduces Cocaine-Seeking Behavior in "Addicted" Mice - Antibiotic that appears to control phobias may also be useful in treating addiction
Oxford BioMedica Announces Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial in Parkinson’s Disease